Table 2.
Propensity score-matched baseline characteristics and COVID-19 test positivity between non-aspirin and aspirin groups.
| Characteristic | Non-Aspirin N = 136 |
Aspirin before COVID-19 Index Date N = 136 |
SMD | Non-Aspirin N = 526 |
Aspirin after COVID-19 Index Date N = 526 |
SMD |
|---|---|---|---|---|---|---|
| Sex, n (%) | 0.030 | 0.023 | ||||
| Male | 84 (61.8) | 86 (63.2) | 299 (56.8) | 305 (58.0) | ||
| Female | 52 (38.2) | 50 (36.8) | 227 (43.2) | 221 (42.0) | ||
| Age, n (%) | 0.128 | 0.052 | ||||
| 20–29 | 0 (0.0) | 0 (0.0) | 3 (0.6) | 6 (1.1) | ||
| 30–39 | 1 (0.7) | 1 (0.7) | 7 (1.3) | 5 (1.0) | ||
| 40–49 | 6 (4.4) | 7 (5.1) | 17 (3.2) | 18 (3.4) | ||
| 50–59 | 14 (10.3) | 17 (12.5) | 41 (7.8) | 47 (8.9) | ||
| 60–69 | 30 (22.1) | 36 (26.5) | 118 (22.4) | 118 (22.4) | ||
| 70–79 | 52 (38.2) | 47 (34.6) | 160 (30.4) | 164 (31.2) | ||
| 80+ | 33 (24.3) | 28 (20.6) | 180 (34.2) | 168 (31.9) | ||
| Region, n (%) | 0.027 | 0.006 | ||||
| Seoul | 17 (12.5) | 22 (16.2) | 93 (17.7) | 86 (16.3) | ||
| Gyeonggi | 41 (30.1) | 36 (26.5) | 158 (30.0) | 155 (29.5) | ||
| Daegu | 17 (12.5) | 17 (12.5) | 63 (12.0) | 72 (13.7) | ||
| Gyeongbuk | 13 (9.6) | 14 (10.3) | 54 (10.3) | 58 (11.0) | ||
| Others | 48 (35.3) | 47 (34.6) | 158 (30.0) | 155 (29.5) | ||
| HTN, n (%) | 112 (82.4) | 108 (79.4) | 0.072 | 401 (76.2) | 397 (75.5) | 0.018 |
| COPD, n (%) | 11 (8.1) | 13 (9.6) | 0.050 | 38 (7.2) | 51 (9.7) | 0.083 |
| Asthma, n (%) | 26 (19.1) | 23 (16.9) | 0.059 | 85 (16.2) | 96 (18.3) | 0.054 |
| CKD, n (%) | 54 (39.7) | 62 (45.6) | 0.118 | 93 (17.7) | 114 (21.7) | 0.097 |
| DM, n (%) | 98 (72.1) | 92 (67.6) | 0.094 | 262 (49.8) | 267 (50.8) | 0.019 |
| CVD, n (%) | 67 (49.3) | 66 (48.5) | 0.015 | 184 (35.0) | 191 (36.3) | 0.028 |
| Charlson Comorbidity Index, n (%) | 0.113 | 0.003 | ||||
| 0 | 11 (8.1) | 12 (8.8) | 42 (8.0) | 44 (8.4) | ||
| 1 | 27 (19.9) | 35 (25.7) | 136 (35.9) | 133 (25.3) | ||
| 2 or more | 98 (72.1) | 89 (65.4) | 348 (66.2) | 349 (66.3) | ||
| Current use of medication, n (%) | ||||||
| Steroid | 35 (25.7) | 36 (26.5) | 0.017 | 54 (10.3) | 59 (11.2) | 0.030 |
| COVID-19, n (%) | ||||||
| Minimally adjusted OR * | 1.00 (reference) | 0.71 (0.34–1.46) |
1.00 (reference) | 0.89 (0.67–1.18) |
||
| Fully adjusted OR † |
1.00 (reference) | 0.63 (0.27–1.45) |
1.00 (reference) | 0.89 (0.64–1.24) |
||
HTN: hypertension, COPD: Chronic obstructive pulmonary disease, CKD: Chronic kidney disease, DM: Diabetes mellitus, CVD: Cerebrovascular disease; * Minimally adjusted: adjustment for age and sex; † Fully adjusted: adjustment for age, sex, and region of residence (Seoul, Gyeonggi, Daegu, Gyeongbuk, others), HTN, COPD, Asthma, CKD, DM, CVD, Charlson Comorbidity Index (0, 1, 2 or more), and current use of steroid; SMD: standardized mean difference.